Beyond Abacavir/3TC: Good News on First-Line Regimens
Positive data emerged this year to support the use of boosted atazanavir and boosted darunavir in treatment-naive patients; raltegravir also looks promising in this population.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)